Pre-market: IDIA.SW Idorsia Ltd (SIX) posts results today 26 Feb 2026: watch CHF 3.62 price reaction
IDIA.SW stock is in focus pre-market ahead of Idorsia Ltd’s earnings release on 26 Feb 2026. The current price is CHF 3.62 and the market will parse revenue, EPS and pipeline updates for trading direction. Investors should watch guidance and commercial progress on daridorexant and aprocitentan for near-term impact on shares.
IDIA.SW stock: earnings preview and expected drivers
Idorsia reports after the market open on 26 Feb 2026 and the key headline will be product revenue versus prior quarter trends. Current metrics show market cap CHF 748,425,990.00, EPS -0.62, and recent average volume 1,458,928.00 shares. Investors will focus on daridorexant sales, partner milestones and reported R&D spend for guidance on operating losses.
IDIA.SW stock earnings: what to watch in the report
Look for reported revenue per product line, any milestone receipts from Janssen or Mochida, and changes to management guidance. Idorsia’s revenue per share TTM equals 1.08 and R&D to revenue runs near 45.32%. A surprise on milestone income or narrower operating losses could trigger a quick re-rate given current sentiment.
IDIA.SW stock analysis: financials, valuation and ratios
Idorsia trades at CHF 3.62 with a P/E of -6.05 and price to sales ratio 3.22. Book value per share is -5.29 and current ratio stands at 1.40, indicating liquidity cover. Free cash flow per share TTM is -0.65 and enterprise value is CHF 1,949,595,990.00, implying elevated EV/sales of 8.38. These metrics show a development-stage biotech with negative earnings and valuation premiums tied to pipeline potential.
IDIA.SW stock technicals and Meyka AI grade
Short-term technicals are mixed: RSI 49.29 and MACD histogram -0.02 signal little trend momentum. Bollinger mid band is CHF 3.78 with an ATR of 0.21, so expect intraday swings around the CHF 3.62 level. Meyka AI rates IDIA.SW with a score of 72.71 out of 100 (B+ / BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.
IDIA.SW stock outlook: forecasts and price targets
Meyka AI’s forecast model projects monthly CHF 4.05, quarterly CHF 5.39, and yearly CHF 5.43 for IDIA.SW stock. Versus the current price CHF 3.62, the model implies upside of 11.88% at one month and 49.93% at one year. Analysts will compare these model levels with company guidance and sector peers in Swiss healthcare.
IDIA.SW stock risks and near-term catalysts
Major risks include clinical setbacks, slower-than-expected product uptake, and volatile milestone timing. Catalysts are stronger daridorexant sales figures, new approvals, and partner milestone announcements. Given average daily volume 568,299.00, liquidity is adequate for active traders but volatility can widen on headline surprises.
Final Thoughts
IDIA.SW stock enters the 26 Feb 2026 earnings window as a development-stage biotech with commercial elements. The shares trade at CHF 3.62 with negative EPS and high EV/sales, so the market will reward clearer revenue trajectories and partnership milestones. Meyka AI’s forecast model projects yearly CHF 5.43, an implied one-year upside of 49.93% versus the present price. That projection balances the pipeline upside against weak free cash flow per share -0.65 and negative operating margins. News on daridorexant uptake or milestone fees would likely tighten valuation gaps to peers in the Swiss healthcare sector. Use the report to check revenue split, cash runway and any guidance change. Meyka AI provides this as an AI-powered market analysis platform; forecasts are model-based projections and not guarantees.
FAQs
When will Idorsia (IDIA.SW) report earnings?
Idorsia’s earnings announcement is scheduled for 26 Feb 2026. Check the company’s investor site for exact timing and the full release to see revenue, EPS and guidance details.
What price does Meyka AI forecast for IDIA.SW stock?
Meyka AI’s model projects yearly CHF 5.43 for IDIA.SW stock, implying about 49.93% upside from CHF 3.62. Forecasts are model-based and not guarantees.
What are the biggest risks for IDIA.SW stock after earnings?
Key risks include weaker product sales, missed milestone income, higher R&D burn, and clinical delays. Any negative guidance or cash-runway concerns could pressure the share price.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.